ACP
BMRN icon

Acuta Capital Partners’s BioMarin Pharmaceuticals BMRN Stock Holding History

Acuta Capital Partners’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-30,000
Closed -$2.78M – 58
2016
Q3 		$2.78M Sell
30,000
-34,000
-53% -$3.2M 1.04% 28
2016
Q2 		$4.98M Buy
+64,000
New +$5.44M 2.39% 13

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Acuta Capital Partners's BMRN Position: Q4 2016 in Review

Acuta Capital Partners sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2016, closing a stake of 30,000 shares — an estimated $2.78M sold.

Acuta Capital Partners first reported a position in BMRN in Q2 2016 and held it in 2 quarters. The position peaked at $4.98M in Q2 2016. 415 funds tracked by Wall St. Rank hold BMRN as of Q4 2016.

  • Acuta Capital Partners reported no remaining BioMarin Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • Acuta Capital Partners sold 30,000 BioMarin Pharmaceuticals shares in Q4 2016, an estimated $2.78M.
  • Acuta Capital Partners first reported a position in BioMarin Pharmaceuticals in Q2 2016 and held it in 2 quarters.
  • Acuta Capital Partners's BioMarin Pharmaceuticals position peaked at $4.98M in Q2 2016.
  • 415 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2016.

Based on Acuta Capital Partners's 13F filing for Q4 2016, filed 13 Feb 2017.